CorMedix Inc. Announces FDA Acceptance of Resubmission of New Drug Application for DefenCath - June 21, 2023

CorMedix Inc. has announced that the US Food and Drug Administration (FDA) has accepted the resubmission of its New Drug Application for DefenCath, a catheter lock solution that is being developed to reduce catheter-related bloodstream infections in patients with kidney failure who are receiving chronic hemodialysis via a central venous catheter. The FDA considers the resubmission as a complete,..

• format_list_bulleted BS
• · 2023. 6. 22.
• textsms

Eloxx Pharmaceuticals Highlights Recent Alport Syndrome Natural History Data Presented at 60th ERA Congress

Eloxx Pharmaceuticals, a leader in ribosomal RNA-targeted genetic therapies for rare diseases, has highlighted recent Alport syndrome natural history data presented at the 60th ERA (European Renal Association) Congress. The RaDaR natural history study indicates that patients with autosomal recessive COL4A4 mutations have the severest form of the disease, with a more rapid progression to kidney f..

• format_list_bulleted BS
• · 2023. 6. 22.
• textsms